Welcome to our dedicated page for Caredx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for CareDx, Inc. (Nasdaq: CDNA), a precision medicine company focused on genomics‑based transplant diagnostics and related solutions. Through these filings, investors and analysts can review how CareDx reports its financial performance, governance changes, and other material events connected to its transplant‑focused business.
CareDx uses Form 8‑K to disclose current events such as quarterly financial results, preliminary annual results, leadership and board appointments, amendments to its bylaws, and information about shareholder derivative litigation settlements. For example, recent 8‑K filings describe revenue by category (testing services, product, and patient and digital solutions), changes in executive roles, adoption of a majority voting standard for director elections, and court approval milestones for a proposed settlement of shareholder litigation.
In addition to current reports, investors typically consult annual reports on Form 10‑K and quarterly reports on Form 10‑Q for more detailed discussions of CareDx’s transplant diagnostics business, segment information, and risk factors. These periodic reports complement the 8‑K disclosures by providing broader context on the company’s operations in non‑invasive molecular testing, lab products, and patient and digital solutions for transplant care.
On Stock Titan, CareDx filings are updated as they become available from EDGAR and are paired with AI‑powered summaries that highlight key points from lengthy documents. These summaries are designed to help readers quickly understand topics such as revenue composition, governance updates, compensation arrangements, and litigation‑related disclosures, while still allowing direct access to the original SEC filings for detailed review.
CareDx Director Peter Maag has reported the sale of 10,000 shares of common stock at a weighted average price of $19.242 per share on June 17, 2025. The transaction was executed pursuant to a Rule 10b5-1 trading plan established on August 21, 2024.
The shares were sold in multiple transactions with prices ranging from $18.80 to $19.52. Following the reported transaction, Maag continues to hold 318,846 shares directly.
- Transaction Type: Sale (S)
- Ownership Type: Direct (D)
- Total Transaction Value: Approximately $192,420
- Trading Plan: Executed under pre-established 10b5-1 plan
This insider sale represents approximately 3% of Maag's direct holdings in CareDx and was conducted under a predetermined trading plan, which helps avoid concerns about insider trading.
CareDx, Inc. (CDNA) – Form 144 filing discloses a proposed sale of 10,570 common shares through Morgan Stanley Smith Barney on the NASDAQ. The shares, acquired as restricted stock units on 14 Jun 2025, carry an aggregate market value of $206,326.40, implying an indicative price of roughly $19.53 per share. The transaction is slated to occur on or about 18 Jun 2025. According to the filing, no other sales were made in the past three months, and the sale represents only ~0.02 % of the 55.68 million shares outstanding, suggesting minimal dilution or market impact. The filer certifies awareness of no undisclosed material adverse information and may be relying on a Rule 10b5-1 trading plan. Relationship to the issuer and filer identity were not provided in the excerpt.